Milataxel is a new taxane that may have several advantages over the currently available
taxanes. The current study is designed to determine the response rate of oral Milataxel
in patients with malignant Mesothelioma. The study specifically targets patients who have
recurring or progressive disease following previous chemotherapy.
Additional locations may be listed on ClinicalTrials.gov for NCT00685204.
See trial information on ClinicalTrials.gov for a list of participating sites.
This is a non-randomized, multicenter, open label, single agent phase II study. Patients
with malignant mesothelioma that has recurred or progressed following chemotherapy, and
who qualify for this study, will receive milataxel 60 mg/m2 orally on Day 1 of a 21 day
cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75
mg/m2 for the second and subsequent cycles. Patients will receive drug for a total of six
cycles. Milataxel administration in excess of six cycles will be permitted at the
discretion of the Investigator if patients have stable or responding disease.
Lead OrganizationTaxolog Inc.